Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.
Take action
Contact the company
📍Recalling firmCipla USA, Inc.10 Independence Blvd · Warren, NJ 07059-2730
✎ GovInfoNow plain-language explainer
Cipla USA, Inc. is recalling Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP unit-dose vials because they may contain less liquid than labeled. This short fill could result in patients receiving an insufficient dose of their medication. The recall affects specific lots distributed nationwide. Read more at govinfonow.com/recall/32756-cipla-recalls-ipratropium-albuterol-inhalation-solution-due-to-short-fill.
“Cipla Recalls Ipratropium/Albuterol Inhalation Solution Due to Short Fill.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/32756-cipla-recalls-ipratropium-albuterol-inhalation-solution-due-to-short-fill. Based on FDA recall #D-0471-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0471-2024%22&limit=1).
Cipla USA, Inc. recalled Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP due to short fill hazards, according to the FDA on March 26, 2024. Owners should contact the company for a refund.
The recall addresses complaints of less fill volume in the respule and few drops of liquid observed in the intact pouch.
Context
GovInfoNow's records show Cipla USA, Inc. has 12 other recalls on record since June 27, 2023. Other recent recalls of similar products include Cipla Cinacalcet Tablets Recall: N-nitroso-cinacalcet Risk (June 29, 2026), Lupin Liraglutide 18mg/3mL Injection Recall: Particulate Matter Hazard (April 24, 2026), and Mallinckrodt Acthar Gel 5mL Vial Recall: Particulate Matter Hazard (August 6, 2026).
How to tell if you have this one
Look for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-dose vials packaged in cartons containing 30 vials (6 pouches of 5 - 3 mL vials). Check the NDC 69097-173-53 and lot numbers IA30390 (Exp 4/30/2025) or IA30517 (Exp 6/30/2025).
Brand
Cipla USA
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Your Lot Numbers
Verify if your product matches NDC 69097-173-53 and lot numbers IA30390 or IA30517.
Contact Your Pharmacist
Speak with your healthcare provider or pharmacist to discuss alternative treatment options if you have the recalled lots.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “USA nationwide.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 15 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0471-2024 (March 26, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0471-2024 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.